Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (2)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page




    The BioNTech / Pfizer vaccine BNT162b2 induces class-switched SARS-CoV-2-specific plasma cells and potential memory B cells as well as IgG and IgA serum and IgG saliva antibodies upon the first immunization

    Authors: Anne Sophie Lixenfeld; inga Kuensting; Emily L. Martin; Vera von Kopylow; Selina Lehrian; Hanna B. Lunding; Jana Sophia Buhre; Janna L. Quack; Moritz Steinhaus; Tobias Graf; Marc Ehlers; Johann Rahmoeller

    doi:10.1101/2021.03.10.21252001 Date: 2021-03-12 Source: medRxiv

    To treat the SARS-CoV-2 virus MESHD, that enters the body through the respiratory tract, different vaccines in particular against the SARS-CoV-2 spike PROTEIN ( S)-protein PROTEIN have been developed or are in the development process. For the BioNTech / Pfizer mRNA vaccine BNT162b2, which is injected twice, protection against COVID-19 MESHD has been described for the first weeks after the second vaccination. The underlying mechanisms of defense and the long-term effectiveness of this vaccine against COVID-19 MESHD are currently under investigation. In addition to the induction of systemic antibodies (Abs), Ab responses in the respiratory tract would help to form a first line of defense against SARS-CoV-2. Furthermore, protection depends on Fab HGNC-part-dependent neutralizing capacities, however, Fc-part-mediated effector mechanisms might also be important. Long-term defense would be based on the induction of long-lived antibody-producing plasma cells (PCs) and memory B cells. Here, we established different assays to analyze anti-SARS-CoV-2-S IgG and IgA Abs in blood serum and saliva as well as SARS-CoV-2-S1-reactive IgG and IgA PCs MESHD and potential memory B cells in the blood of individuals upon their first immunization with BNT162b2. We show that the vaccine induces in particular anti-SARS-CoV-2-S IgG1 and IgG3 HGNC as well as IgA1 HGNC and in some individuals also IgG2 and IgA2 serum Abs. In the saliva, we found no anti-SARS-CoV-2-S IgA, but instead IgG Abs. Furthermore, we found SARS-CoV-2-S reactive IgG+ blood PCs MESHD and potential memory B cells as well as SARS-CoV-2-S reactive IgA+ PCs and/or potential memory B cells in some individuals. Our data suggest that the vaccine induces a promising CD4+ T cell-dependent systemic IgG1 and IgG3 HGNC Ab response with IgG+ PCs and potential memory B cells. In addition to the systemic IgG response, the systemic IgA and saliva IgG response might help to improve a first line of defense in the respiratory tract against SARS-CoV-2 and its mutants.

    SARS-CoV-2 infection MESHDs and antibody responses among health care workers in a Spanish hospital after a month of follow-up

    Authors: Gemma Moncunill; Alfredo Mayor; Rebeca Santano; Alfons Jimenez; Marta Vidal; Marta Tortajada; Sergi Sanz; Susana Mendez; Anna Llupia; Ruth Aguilar; Selena Alonso; Diana Barrios; Carlo Carolis; Pau Cistero; Eugenia Choliz; Angeline Cruz; Silvia Fochs; Chenjerai Jairoce; Jochen Hecht; Montserrat Lamoglia; Mikel Martinez; Javier Moreno; Robert Mitchell; Natalia Ortega; Nuria Pey; Laura Puyol; Marta Ribes; Neus Rosell; Patricia Sotomayor; Sara Torres; Sarah Williams; Sonia Barroso; Anna Vilella; Antoni Trilla; Pilar Varela; Carlota Dobano; Alberto L Garcia-Basteiro

    doi:10.1101/2020.08.23.20180125 Date: 2020-08-25 Source: medRxiv

    Background. At the peak of the COVID-19 MESHD COVID-19 MESHD pandemic in Spain, cumulative prevalence of SARS-CoV-2 infection MESHD in a cohort of 578 randomly selected health care workers (HCW) from Hospital Clinic de Barcelona was 11.2%. Methods. A follow-up survey one month after the baseline (April-May 2020) measured SARS-CoV-2 infection MESHD by real time reverse-transcriptase polymerase chain reaction (rRT-PCR) and IgM, IgA, IgG and subclasses to the receptor-binding domain of the SARS-CoV-2 spike PROTEIN protein by Luminex. Prevalence of infection was defined by a positive SARS-CoV-2 rRT-PCR and/or antibody seropositivity. Results. The cumulative prevalence of infection at month 1 was 14.9% (84/565) and the seroprevalence 14.5% (82/565) for IgM and/or IgG and/or IgA. We found 25 (5%) new infections in participants without previous evidence of infection at baseline (501) and two participants seroreverted for IgM and/or IgG and/or IgA. Among seropositive participants at baseline, IgM and IgA levels generally declined at month 1 (antibody decay rates of 0.49 (95% CI, 0.40-0.60) and 0.34 (95% CI, 0.26-0.44)), respectively. Eight percent of the participants seroreverted for IgM and 11% for IgA. Subjects reporting COVID-19 MESHD-like symptoms and laboratory and other technicians had higher risk of infection. The most frequent subclass responses were IgG1 and IgG2, followed by IgG3 HGNC, with higher levels of IgG1, and only IgA1 HGNC but no IgA2 was detected. Conclusions. Our findings highlight the importance of a continuous and improved surveillance of SARS-CoV-2 infections MESHD in HCW, particularly in high risk groups. The decay of IgA and IgM levels have implications for seroprevalence studies using these isotypes.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.